Cost-benefit analysis of medicinal treatment for gastric ulcers. Long-term model including healing and recurrence.
Cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA) are increasingly being used in medical practice and in health policy making. The choice among alternative treatments, the aim of a more efficient use of limited resources and the wider goal of cost containment, are so many reasons for CBA and CEA. This paper addresses the rather unexplored field of long-term cost-benefit analysis. Gastric ulcer, which is a recurrent disease is taken as a case study. Mathematical modelling is used for situation analysis of alternative long-term intervention strategies. The use of recurrence in the model makes the results of earlier CBA's based on the healing of a single episode, open to question. The paper holds important lessons for both the theoretical aspects of CBA and for its utilization in health policy formulation.
D002927:Cimetidine / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005778:Gefarnate / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D008962:Models, Theoretical; D011090:Polyenes / Q000627:therapeutic use; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000191:economics